Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.38 |
| ▸ | CTSV | O60911 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17049468 | 1.00 | CNR1 (0.42) | CNR1CNR2ATMALDH1A1LMNA | |
| SCHEMBL17049465 | 1.00 | CNR1 (0.42) | CNR1CNR2ATMALDH1A1LMNA | |
| SCHEMBL2763063 | 1.00 | CNR1 (0.42) | CNR1CNR2ATMALDH1A1LMNA | |
| SCHEMBL2763061 | 1.00 | CNR1 (0.42) | CNR1CNR2ATMALDH1A1LMNA | |
| SCHEMBL17049473 | 0.91 | MAOB (0.40) | CNR1CNR2ATMALDH1A1LMNA | |
| SCHEMBL13376358 | 0.87 | MAP4K4 (0.41) | ATMALDH1A1LMNASMN1; SMN2MAP4K4 | |
| SCHEMBL20810492 | 0.87 | HPGD (0.42) | ATMALDH1A1LMNASMN1; SMN2MAP4K4 | |
| SCHEMBL2764163 | 0.87 | CNR2 (0.48) | CNR1CNR2ATMALDH1A1LMNA | |
| SCHEMBL13302517 | 0.87 | CNR2 (0.48) | CNR1CNR2ATMALDH1A1LMNA | |
| SCHEMBL2764166 | 0.87 | CNR2 (0.48) | CNR1CNR2ATMALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| WO-2016128771-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | CANBEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | WO | disclosed |
| US-20160107984-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2016-04-21 | — | — | US | disclosed |
| US-20160107984-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2016-04-21 | — | — | US | disclosed |
| US-9120723-B2 | Modulator | CANBEX THERAPEUTICS LIMITED (GB) | 2015-09-01 | — | — | US | disclosed |
| US-9120723-B2 | Modulator | CANBEX THERAPEUTICS LIMITED (GB) | 2015-09-01 | — | — | US | disclosed |
| US-9024067-B2 | Process for preparing carboxylic acid amides useful in the treatment of muscular disorders | CANBEX THERAPEUTICS LIMITED (GB) | 2015-05-05 | — | — | US | disclosed |
| US-9024067-B2 | Process for preparing carboxylic acid amides useful in the treatment of muscular disorders | CANBEX THERAPEUTICS LIMITED (GB) | 2015-05-05 | — | — | US | disclosed |
| US-20130123356-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2013-05-16 | — | — | US | disclosed |
| US-20120101301-A1 | PROCESS FOR PREPARING CARBOXYLIC ACID AMIDES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS | UCL BUSINESS PLC (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101301-A1 | PROCESS FOR PREPARING CARBOXYLIC ACID AMIDES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS | UCL BUSINESS PLC (GB) | 2012-04-26 | — | — | US | disclosed |
| WO-2010116116-A1 | PROCESS FOR PREPARING CARBOXYLIC ACID AMIDES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS | UCL BUSINESS PLC (GB) | 2010-10-14 | — | — | WO | disclosed |
| US-20100144876-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2010-06-10 | — | — | US | disclosed |
| US-20100144876-A1 | MODULATOR | UNIVERSITY COLLEGE LONDON (GB) | 2010-06-10 | — | — | US | disclosed |
| EP-2177503-A1 | MODULATORS OF CANNABINOID RECEPTORS | UCL Business PLC (GB) | 2010-04-21 | — | — | EP | disclosed |
| US-7696382-B2 | Modulator | UNIVERSITY COLLEGE LONDON (GB) | 2010-04-13 | — | — | US | disclosed |
| US-7696382-B2 | Modulator | UNIVERSITY COLLEGE LONDON (GB) | 2010-04-13 | — | — | US | disclosed |
| US-20080114062-A1 | Modulator | UNIVERSITY COLLEGE LONDON WOLFSON INSTITUTE FOR BIOMEDICAL RESEARCH (GB) | 2008-05-15 | — | — | US | disclosed |
| US-20080114062-A1 | Modulator | UNIVERSITY COLLEGE LONDON WOLFSON INSTITUTE FOR BIOMEDICAL RESEARCH (GB) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114062-A1 | Modulator | CHRNA3, CHRM3, NR3C2 | CNR1 7/4885CNR2 16/4885ATM 4322/4885 |
| US-20160107984-A1 | MODULATOR | CHRNA3, CHRNB3, CHRM3 | CNR1 25/4885CNR2 26/4885ATM 4443/4885 |
| US-20130123356-A1 | MODULATOR | MRGPRX2, NR3C2, MC2R | CNR1 90/4885CNR2 82/4885ATM 4751/4885 |
| US-20120101301-A1 | PROCESS FOR PREPARING CARBOXYLIC ACID AMIDES USEFUL IN THE TREATMENT OF MUSCULAR DISORDERS | CPT1B, MUSK, C1R | CNR1 63/4885CNR2 106/4885ATM 3139/4885 |
| US-20100144876-A1 | MODULATOR | CHRNA3, CHRM3, NR3C2 | CNR1 7/4885CNR2 16/4885ATM 4322/4885 |
| US-20180116983-A1 | COMPOUNDS FOR TREATING DISORDERS ASSOCIATED WITH BK CHANNEL MODULATION | HCN4, KCNJ4, KCNQ4 | CNR1 66/4885CNR2 79/4885ATM 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.